Subscribe To

Price Alert Latest News Economic Calendar News

CCXI / Why ChemoCentryx Shares Are Rising

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis. “European Union approval of TAVNEOS represents the third major global sector to recognize the value of this long-awaited new treatment for the debilitating and often deadly disease of ANCA-associated vasculitis,” said Thomas J. Read More

Demo Live Account See Partner Details

Content Topics

Ishares

Evolved

Innovative

Healthcare

Etf

Ieih

Chemocentryx

Rising

Stock

CCXI

Posted: Jan 19 2022, 11:29

Author Name: Benzinga

CCXI News

By Benzinga
August 4, 2022

ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why

Shares of ChemoCentryx, Inc. (NASDAQ: CCXI) are skyrocketing Thursday following a groundbreaking announcement for the biopharmaceutical company. Why I

By Pulse2
August 4, 2022

Why Amgen (AMGN) Is Buying ChemoCentryx (CCXI) For $4 Billion In Cash

Amgen (AMGN) is buying ChemoCentryx (CCXI) for $4 billion in cash. These are the details.

By MarketBeat
May 9, 2022

ChemoCentryx: A Biotech Stock Well Worth the Risk

In the wake of its first quarter earnings report, ChemoCentryx ran as much as 25% on Friday as the broader market fell. The move could mark an importa

By Zacks Investment Research
May 6, 2022

ChemoCentryx (CCXI) Q1 Earnings and Sales Miss Estimates

ChemoCentryx (CCXI) posts a wider-than-anticipated Q1 loss and a revenue lag. However, product sales of CCXI's recently approved drug Tavneos grow fiv

By Benzinga
May 6, 2022

Why ChemoCentryx Shares Are Popping Off

ChemoCentryx Inc (NASDAQ: CCXI) shares are trading higher by 21.45% at $19.00 after the company reported first-quarter results. ChemoCentryx reported

By Seeking Alpha
May 5, 2022

ChemoCentryx, Inc. (CCXI) CEO Dr. Thomas Schall on Q1 2022 Results - Earnings Call Transcript

ChemoCentryx, Inc. (NASDAQ:CCXI ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Dr. Thomas Schall – Chairman, Preside

By Zacks Investment Research
May 5, 2022

ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hol

By Zacks Investment Research
March 2, 2022

ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates

ChemoCentryx (CCXI) posts a wider year-over-year loss in the fourth quarter and sales miss estimates. Lead drug Tavneos has been launched in the Unite

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.